Plasma ctDNA determination in the diagnosis and treatment of colorectal cancer

doi:10.3969/j.issn.1673-8640.2020.09.022

Abstract

Abstract:

The incidence and mortality of colorectal cancer are increasing. It is because of the lack of suitable means for early screening,and the compliance of colonoscopy among patients is not ideal. Another reason is the limitations of treatment methods,and some patients' lesions can not be resected. There are uncertainties in the efficiency of chemotherapy and radiotherapy,and targeted therapy is only available for certain population. Through molecular diagnostic techniques,plasma circulating tumor DNA（ctDNA） can be determined,and early screening,prognosis and chemotherapeutic drug response can be performed,which can guide clinical treatment. The review focuses on the determination of plasma ctDNA and its application in the diagnosis and treatment of colorectal cancer.

Key words: Circulating tumor DNA, Colorectal cancer, Targeted therapy

CLC Number:

R446.7

CHEN Xinning, WU Shengchao, GUO Wei, WANG Beili. Plasma ctDNA determination in the diagnosis and treatment of colorectal cancer[J]. Laboratory Medicine, 2020, 35(9): 948-951.

Figures/Tables 1

References 32

[1]	SONG L L,LI Y M.Current noninvasive tests for colorectal cancer screening:an overview of colorectal cancer screening tests[J]. World J Gastrointest Oncol,2016,8(11):793-800.
[2]	房静远,时永全,陈萦晅,等. 中国结直肠癌预防共识意见(2016年,上海)[J]. 中华消化杂志,2016,36(11):721-733.
[3]	BRENNER H,KLOOR M,POX C P.Colorectal cancer[J]. Lancet,2014,383(9927):1490-1502.
[4]	SIRAVEGNA G,MARSONI S,SIENA S,et al.Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol,2017,14(9):531-548.
[5]	YÖRÜKER E E,HOLDENRIEDER S,GEZER U. Blood-based biomarkers for diagnosis,prognosis and treatment of colorectal cancer[J]. Clin Chim Acta,2016,455:26-32.
[6]	王飞. 四期不可根治性切除结直肠癌的临床特征及治疗方案评估[D]. 杭州:浙江大学,2016.
[7]	付极,林国乐. 分子诊断技术在结直肠癌个体化精准治疗中的应用[J]. 中华胃肠外科杂志,2016,19(1):22-26.
[8]	GARCÍA-FONCILLAS J,ALBA E,ARANDA E,et al. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients:an expert taskforce review[J]. Ann Oncol,2017,28(12):2943-2949.
[9]	JAHR S,HENTZE H,ENGLISCH S,et al.DNA fragments in the blood plasma of cancer patients:quantitations and evidence for their origin from apoptotic and necrotic cells[J]. Cancer Res,2001,61(4):1659-1665.
[10]	BETTEGOWDA C,SAUSEN M,LEARY R J,et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med,2014,6(224):224ra24.
[11]	REINERT T,HENRIKSEN T V,CHRISTENSEN E,et al.Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages Ⅰ to Ⅲ colorectal cancer[J]. JAMA Oncol,2019,5(8):e190528.
[12]	DIEHL F,SCHMIDT K,CHOTI M A,et al.Circulating mutant DNA to assess tumor dynamics[J]. Nat Med,2008,14(9):985-990.
[13]	TOLEDO R A,CUBILLO A,VEGA E,et al.Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab[J]. Oncotarget,2017,8(21) :35289-35300.
[14]	HIGGINS M J,JEJOVAC D,BARNATHAN E,et al.Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood[J]. Clin Cancer Res,2012,18(12):3462-3469.
[15]	张博诚,张显玉,孙根,等. 液滴数字PCR在乳腺癌精准治疗中的应用[J]. 中国肿瘤临床,2017,44(3):146-149.
[16]	ZHANG Y C,ZHOU Q,WU Y L .The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer[J]. J Hematol Oncol,2017,10(1):167.
[17]	于鑫淼,金锋. 二代测序技术在乳腺癌精准治疗中的应用[J]. 中华乳腺病杂志(电子版),2018,12(4):238-241.
[18]	CHO Y T,SU H,WU W J,et al.Biomarker characterization by MALDI-TOF/MS[J]. Adv Clin Chem,2015,69:209-254.
[19]	ZHANG Y V,JACKSON T .质谱技术在临床实验室的应用[J]. 检验医学,2019,34(1):1-7.
[20]	SHERWOOD J L,MÜLLER S,ORR M C,et al. Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour[J]. PLoS One,2014,9(6):e100566.
[21]	曹紫阳,吴伟,侯立坤,等. 微滴数字PCR与Super-ARMS PCR检测非小细胞肺癌患者表皮生长因子受体(EGFR)酪氨酸激酶抑制剂治疗耐药后血浆游离DNA EGFR基因T790M突变的对比分析[J] . 中华病理学杂志,2018,47( 12 ):910-914.
[22]	NG S B,CHUA C,NG M,et al.Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery[J]. Sci Rep,2017,7:40737.
[23]	REINERT T,SCHØLER L V,THOMSEN R,et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery[J]. Gut,2016,65(4):625-634.
[24]	WANG Y,LI L,COHEN J D,et al.Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer[J]. JAMA Oncol,2019,5(8):1118-1123.
[25]	ARENA S,BELLOSILLO B,SIRAVEGNA G,et al.Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer[J]. Clin Cancer Res,2015,21(9):2157-2166.
[26]	王子元,梁婷玉,陈佳,等. 结肠直肠癌KRAS、NRAS、BRAF基因突变及其与临床病理特征、p53蛋白表达间相关性研究[J]. 诊断学理论与实践,2018,17(6):687-693.
[27]	姚宏伟,吴鸿伟,刘荫华. 美国癌症联合委员会第八版结直肠癌分期更新及其“预后和预测”评价体系[J]. 中华胃肠外科杂志,2017,20(1):24-27.
[28]	VIDAL J,MUINELO L,DALMASES A,et al.Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients[J]. Ann Oncol,2017,28(6):1325-1332.
[29]	LOUPAKIS F,CREMOLINI C,MASI G,et al.Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer[J]. N Engl J Med,2014,371(17):1609-1618.
[30]	STRICKLER J H,LOREE J M,AHRONIAN L G,et al.Genomic landscape of cell-free DNA in patients with colorectal cancer[J]. Cancer Dis,2018,8(2):164-173.
[31]	BERTOTTI A,PAPP E,JONES S,et al.The genomic landscape of response to EGFR blockade in colorectal cancer[J]. Nature,2015,526(7572):263-267.
[32]	MONTAGUT C,DALMASES A,BELLOSILLO B,et al.Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer[J]. Nat Med,2012,18(2):221-223.

检测方法	灵敏度/%	检测周期/d	优势
BEAMing	0.01	7~10	绝对定量
MALDI-TOF	0.10	1~2	中等通量,对样本投入量要求低
ARMS-PCR	0.01~0.20	1	有获批的商品化试剂盒
ddPCR	0.01	<1	绝对定量,对样本投入量要求低,重复性好
NGS	0.10~0.50	8~10	高通量,可以检测未知突变

检测方法	灵敏度/%	检测周期/d	优势
BEAMing	0.01	7~10	绝对定量
MALDI-TOF	0.10	1~2	中等通量,对样本投入量要求低
ARMS-PCR	0.01~0.20	1	有获批的商品化试剂盒
ddPCR	0.01	<1	绝对定量,对样本投入量要求低,重复性好
NGS	0.10~0.50	8~10	高通量,可以检测未知突变